BackSCIENCE_HEALTH
Endocrine Society renames PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to speed diagnosis and care
The Endocrine Society announced Polycystic Ovary Syndrome (PCOS) will be renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect the condition's endocrine, metabolic, and ovarian dysfunction. The move cites arguments published in The Lancet about the term's inaccuracy and potential diagnostic delays and stigma. A global implementation strategy, including a transition period and education, is reportedly underway with input from more than 50 patient and professional organisations.
Why It Matters
The new name aims to reduce stigma and delays in diagnosis by moving away from the ovarian-cyst focus and recognizing the full spectrum of endocrine, metabolic, and related features.
Timeline
5 Events
Stakeholder involvement in the naming process
May 13, 2026
More than 50 patient and professional organisations, including the Endocrine Society, participated in developing the new name.
Scope of PMOS features and impacts described
May 13, 2026
The article describes PMOS as underpinned by endocrine disturbances in insulin androgens and neuroendocrine and ovarian hormones, with metabolic, reproductive, psychological, and dermatological features, and risks such as obesity, type 2 diabetes, hypertension, infertility, and endometrial cancer.
Global implementation strategy outlined
May 13, 2026
A global implementation strategy is reportedly underway, including a transition period, education, and alignment with health systems and disease classification.
Rationale for the name change and diagnosis timing
May 13, 2026
The rationale notes that PCOS is inaccurate as it emphasizes cysts, and diagnosing based on cysts contributes to delays, stigma, and knowledge gaps; omitting cysts and capturing endocrine, metabolic, and ovarian dysfunction is seen as improving diagnostic accuracy.
Endocrine Society announces renaming PCOS to PMOS
May 13, 2026
The Endocrine Society declares Polycystic Ovary Syndrome will be renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to better reflect the condition's endocrine, metabolic, and ovarian dysfunction and to address misconceptions linked to the idea of ovarian cysts.